Pantoxon (Ceftriaxone Disodium Salt Hemiheptahydrate)

Ceftriaxone, the active ingredient in Pantoxon, is a third‑generation cephalosporin presented as an injectable solution for intramuscular use. It treats a range of serious bacterial infections in adults and children. GNH USA supplies Pantoxon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ceftriaxone is a broad‑spectrum third‑generation cephalosporin used to treat serious bacterial infections.

- Community‑acquired pneumonia: rapid bacterial eradication leading to clinical recovery. - Meningitis: penetrates the cerebrospinal fluid to eliminate causative pathogens. - Gonorrhea: effective against Neisseria gonorrhoeae, preventing disease progression. - Urinary tract infections: clears uropathogens causing uncomplicated and complicated UTIs. - Skin and soft tissue infections: resolves cellulitis and wound infections. - Intra‑abdominal infections: treats polymicrobial infections within the abdominal cavity.

Ceftriaxone may cause a variety of adverse reactions ranging from mild to severe.

Common Side Effects: - Injection site pain: discomfort at the intramuscular injection site. - Diarrhea: mild to moderate loose stools. - Nausea: feeling of unease or upset stomach. - Rash: skin redness or mild eruption. - Elevated liver enzymes: transient increase in hepatic transaminases. - Transient hyperbilirubinemia: mild rise in bilirubin levels.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Clostridioides difficile‑associated diarrhea: severe colitis. - Stevens‑Johnson syndrome: extensive skin and mucous membrane involvement. - Hemolytic anemia: destruction of red blood cells. - Thrombophlebitis: inflammation of a vein with clot formation. - Renal impairment: acute kidney injury, especially with concomitant nephrotoxins.

Ceftriaxone requires careful clinical monitoring to ensure safe use. - Renal function assessment: adjust use in patients with impaired kidney function. - Hepatic monitoring: observe liver enzymes during prolonged therapy. - Neonatal dosing: use reduced doses for infants under 28 days. - Known hypersensitivity: avoid in patients with documented cephalosporin allergy. - Biliary sludging risk: monitor patients with gallbladder disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ceftriaxone can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Calcium‑containing solutions: precipitate formation when mixed intravenously. - Bile acid sequestrants: reduce ceftriaxone absorption. - Warfarin: may enhance anticoagulant effect, increasing bleeding risk. - Aminoglycosides: combined nephrotoxicity potential. - Live vaccines: may diminish vaccine efficacy.

Moderate Interactions (Monitor Closely): - Diuretics: may affect electrolyte balance. - Antacids: can alter drug excretion. - Oral contraceptives: possible reduction in contraceptive effectiveness. - Probenecid: decreases renal clearance, raising ceftriaxone levels. - Carbapenems: may increase risk of seizures when co‑administered.